Create your Personal Health Record and unlock support built around you
- Treatments and trials you qualify for
- Education for your stage of care
- Financial support for your medications
- Solutions to your side effects
Joining a Clinical Trial for Adrenal Cancer
A clinical trial is a research study that tests a medical treatment in people. Trials look at new drugs, new drug combinations, new ways of doing surgery or radiation, new imaging tests, and new ways of managing side effects. Every treatment your doctor offers you today became a standard treatment because people with your disease agreed to take part in a trial first. A trial is not an experiment done to you without a plan. It is a carefully written study with rules, safety monitoring, and independent review, and you choose whether to take part.
Clinical trials matter unusually much in adrenal cancer. This series is centered on adrenocortical carcinoma (ACC), a cancer that starts in the outer layer of the adrenal gland. Because so few people are diagnosed each year, there has never been a large pool of patients to study, and research has moved slowly. Mitotane is the only drug specifically approved for adrenal cortical cancer. For advanced disease, the standard first choice is mitotane combined with etoposide, doxorubicin, and cisplatin, a combination known as EDP plus mitotane. That combination was confirmed as the better of the two leading options by the FIRM-ACT trial, whose results were published in 2012, and the individual drugs in it are older still. In other words, the backbone of adrenal cancer treatment has not changed in a long time. New options will only arrive through trials.
Progress in this disease depends on countries working together. No single hospital, and in most cases no single country, sees enough patients to answer a research question alone. That is why international groups such as the European Network for the Study of Adrenal Tumours (ENS@T) and the National Cancer Institute's My Pediatric and Adult Rare Tumor Network (MyPART) exist. They pool patients, tissue samples, and long-term outcome data into shared registries so that questions no one hospital can answer become answerable. When you join a trial or a registry for a rare cancer, your information carries more weight than it would in a common cancer, simply because there is so little of it.
For a cancer this rare, a clinical trial is a mainstream option, not a last resort. A specialist at a high-volume adrenal center may raise trials at your very first visit, while you are still deciding about surgery or first drug treatment, rather than only after standard options have run out. Many patients assume a trial means nothing else is left, or that they will be treated as a guinea pig. Neither is true here. In adrenal cancer, asking about trials early gives you more choices, not fewer, because some trials only accept people who have not yet had certain treatments. This guide explains how trials work, how to find them, and how insurance coverage usually works in the United States. Talk with your own care team before making any decision, since only they know your full medical picture.
Should I Join a Clinical Trial?
Cancer clinical trials are organized into phases, and each phase asks a different question.
Phase 1 trials are usually small and ask whether a new treatment is safe in people and what dose to use.
Phase 2 trials are larger and ask whether the treatment seems to work against a specific cancer.
Phase 3 trials are larger still and compare the new approach against the current standard treatment to see which works better.
Phase 4 trials happen after a drug is already approved and follow long-term safety and how the drug performs in everyday practice. In rare cancers like ACC, many available trials are phase 1 or phase 2, and some are "basket" trials that enroll people with many different cancers that share the same genetic change.
In a randomized trial, a computer assigns you to one of the study groups by chance rather than by choice. This sounds impersonal, but it is the fairest way to make sure the groups are similar so the comparison means something. This is where the biggest myth about cancer trials shows up. Many people believe they might be given a sugar pill instead of treatment. In cancer trials, that is almost never how it works. The control group receives the current standard treatment for the disease. A placebo, which is an inactive substance, is generally only used when there is no known effective treatment to compare against, or it is added on top of standard treatment so that both groups still get real care. The consent documents must tell you exactly which groups exist and what each group receives, so ask directly and get the answer in plain language.
Informed consent is the process of learning what a trial involves before you agree to it, and it does not end when you sign the form. You should receive a written document explaining the purpose, the schedule of visits and tests, the known and possible side effects, the alternatives to joining, and your rights. You can take it home, read it with family, and bring questions back. If new safety information appears while the trial is running, the team must tell you, and you may be asked to sign an updated consent. Consent is an ongoing conversation, not a single signature at the start.
Every trial has eligibility criteria, which are rules about who can join. These often cover the exact type and stage of cancer, which treatments you have already had, your organ function on blood tests, and other health conditions. Criteria can feel arbitrary and frustrating, especially if you miss out by a small margin. They exist for two reasons: to protect you from a treatment that could be unsafe given your situation, and to keep the study group similar enough that the results actually answer the question. If you do not qualify for one trial, ask whether you might qualify for another, or whether the study has a separate group for people in your situation.
The honest balance of benefits and risks looks like this.
Possible benefits: You may get access to a promising treatment before it is widely available. You are usually watched more closely than in routine care, with extra scans and lab work. Your participation helps future patients with a disease that badly needs better options.
Possible risks: The new treatment may not work for you. It may cause side effects that are unexpected or worse than standard treatment. You may need more visits, more tests, and more travel than usual.
The most important point: A trial may bring you no personal benefit at all. That is a real possible outcome, and a trustworthy research team will say so out loud. If anyone promises you the trial will work, treat that as a warning sign.
You can leave at any time: Joining a trial is voluntary, and so is staying in it. You may withdraw at any point for any reason, and your regular medical care and your relationship with your care team will not be affected. Tell the team before you stop so they can arrange safe follow-up.
Finding an adrenal cancer trial takes more effort than finding one for a common cancer, so use several routes at once.
HealthTree's Clinical Trials Finder: Pulls from the public United States registry of studies worldwide. Search "adrenocortical carcinoma" and also search "adrenal cancer" and "adrenal tumor", since studies are labeled inconsistently.
The NCI clinical trials search: Use the National Cancer Institute's trial finder, which lists NCI-supported studies and lets you filter by location and cancer type.
Ask your endocrinologist or oncologist directly: Ask, "Are there any clinical trials I should be considered for, here or anywhere else?" Specialists often know about studies that are not easy to find online, or that are about to open.
Contact an NCI-designated cancer center: These centers run most of the trials in the United States. You can find one near you through NCI's Find a Cancer Center directory. Many will review your records remotely before you travel.
NCI MyPART: The My Pediatric and Adult Rare Tumor Network adrenocortical carcinoma page is built specifically for rare tumors, including ACC in children and young adults, and it exists partly to connect patients with research.
International networks and registries: ENS@T coordinates adrenal tumor research across Europe, maintains registries and biobanks, and lists its own trials. Its centers of excellence map can help families outside the United States find an experienced center.
HealthTree's registry: Contribute your medical information with 1,000s of others in HealthTree's registry by clicking the button below.
Click to connect your medical records and contribute to our registry
Because adrenal cancer is so rare, very few local or community hospitals run trials for it. The nearest open study may be several hours away, in another state, or in another country. That is not a reason to skip trials, but it is a reason to ask early rather than after other options have run out, because referral, records review, insurance approval, and travel planning all take weeks. One current example is the ADIUVO-2 trial, which is testing mitotane alone against mitotane plus cisplatin and etoposide after surgery in people with stage 1 to stage 3 ACC at high risk of the cancer coming back. ENS@T lists ADIUVO-2 as an ongoing trial that is active at 18 sites in France, Germany, and Sweden, with 3 locations currently in the United States. Michigan, Missouri, and Texas, but trial status changes often, so always confirm whether a specific study is currently enrolling before you count on it.
Two clarifications that trip people up when they search. Cancer that started somewhere else, such as the lung, kidney, or breast, and then spread to the adrenal gland is called an adrenal metastasis. That is not adrenal cancer, and trials for it are trials for the original cancer type, so search under that diagnosis instead. Separately, most adrenal masses found by accident on a scan, often called incidentalomas, turn out to be benign and are not cancer at all. Those masses need a proper hormone and imaging workup, described in our guide on how adrenal cancer is diagnosed, but they usually do not lead to cancer treatment or cancer trials.
Pheochromocytoma is a different adrenal cancer and works differently
Pheochromocytoma and paraganglioma (PPGL) arise from the adrenal medulla, the inner core of the gland, rather than from the cortex. These tumors are not ACC, and their trials are not interchangeable with ACC trials. PPGL tumors often release adrenaline-type hormones called catecholamines, which cause blood pressure surges, pounding headaches, sweating, and racing heartbeat. They are diagnosed with metanephrine testing and with specialized scans such as MIBG or DOTATATE imaging, and hereditary changes in genes including SDHx, VHL, RET, and NF1 are common. Because of all that, PPGL research follows its own path, with studies of radioactive treatments given through the bloodstream, targeted drugs, and somatostatin-based therapies rather than EDP plus mitotane. If you have PPGL, search trials under "pheochromocytoma" and "paraganglioma", ask for a center that specializes in these tumors, and read the NCI pheochromocytoma and paraganglioma treatment summary rather than ACC material.
Before you enroll, ask these questions and write down the answers.
What is this trial trying to find out, and what phase is it?
What treatment will I get, what will the other groups get, and is any group receiving a placebo?
What are the known side effects, and how do they compare with standard treatment?
How many extra visits, scans, and blood draws will I need, and where do they happen?
What happens if the treatment does not work, or if I need to stop partway through?
Who pays for what, and will my insurance be billed?
Who do I call, day or night, if something goes wrong?
Will I learn the results of the study, and will I be told which group I was in?
Will My Insurance Cover a Clinical Trial?
Under the Affordable Care Act, most health plans in the United States must cover the routine patient care costs of a qualifying individual in an approved clinical trial for cancer or another life-threatening disease. The law also says a plan cannot drop you, deny you coverage, or refuse to let you join a plan because you are taking part in an approved trial, and it cannot deny coverage of the routine items and services it would otherwise pay for. This protection is written into federal law at 42 U.S. Code 300gg-8. It applies to trials that are federally funded, conducted under an investigational new drug application, or otherwise approved as described in that section.
The key idea is the split between two kinds of costs. Routine patient care costs are the things you would need anyway if you were being treated outside the study: office visits, hospital stays, standard scans and lab tests, and management of side effects. Insurance generally covers these. Research costs are the things that exist only because of the study: the investigational drug itself, extra tests done purely to collect research data, and the study staff's time. The trial sponsor generally covers these, which is why the study drug is usually provided free of charge. Ask for this breakdown in writing before you enroll, because the exact line between the two categories varies from study to study. The National Cancer Institute's page on paying for clinical trials walks through this in more detail.
Expect to deal with prior authorization, which is your plan's advance approval for a service. Ask the research coordinator to send the plan the trial protocol, the list of routine services, and a letter of medical necessity, and get the approval number in writing before your first study visit. If the plan says no, you have the right to appeal. Start with an internal appeal to the plan itself, and if that fails, ask about external review by an independent reviewer. Appeals succeed more often than people expect, especially when the letter explains that the requested item is routine care that the plan would cover outside the study. Keep a running file of every call, name, date, and reference number. NCI's page on managing cancer care costs has practical guidance on tracking all of this.
The out-of-network problem comes up far more often in rare cancers than in common ones, and adrenal cancer is a good example. Because the only open trial may be at a distant academic center, that center is frequently outside your plan's network, which can mean higher cost sharing or no coverage at all. Two practical requests can help. First, ask the plan for a network gap exception, sometimes called a network adequacy exception, which argues that no in-network provider offers this care, so the distant center should be paid at in-network rates. Second, ask the hospital and the plan about a single case agreement, a one-time contract covering your specific care at that site. Both requests are stronger when your doctor documents that no comparable option exists closer to home, which is a reasonable statement for a cancer this rare. Also confirm whether the plan will cover the follow-up scans and hormone tests you will still need at home between study visits.
Travel, lodging, meals, parking, childcare, and lost wages are real costs, and insurance almost never pays them. Some trials include a stipend for travel or provide lodging, especially studies run at government or academic centers, so ask whether yours does. Beyond that, cancer centers keep lists of assistance programs, hospital-based lodging houses, discounted hotel rates, and volunteer flight and ground transportation programs. Ask about family and medical leave protections and about intermittent leave if you are working, since study visits are often spread out. Three people at the cancer center exist to help with exactly this: the financial navigator or financial counselor, who handles benefits, authorizations, and assistance applications; the research coordinator or research nurse, who knows the study budget and what the sponsor pays for; and the oncology social worker, who connects you to travel, lodging, and income support. Our guide on adrenal cancer support has more on these resources, and NCI's Finding Cancer Care page covers insurance and support services more broadly.